Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

Advances in clinical cardiology

Three studies being presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La., highlight the breadth of research propelling advances in clinical cardiology.

3 Apr 2007

U.S. consumers' health care concerns

USA Today on Monday published three articles addressing U.S. consumers' health care concerns as part of a week-long series titled "Prescription for Change," which examines possible improvements to the U.S. health care system.

16 Oct 2006

Built-in blocker - drug and antidote in the same molecule

In cases of serious side effects or overdoses of medications, it can be vital to have a fast-acting antidote on hand.

2 Oct 2006

Tenecteplase study halted

World Congress of Cardiology 2006 - Thrombolytic Therapy, given during cardiopulmonary resuscitation (CPR) in out-ofhospital cardiac arrests, may be no better than placebo.

6 Sep 2006

Preventing bleeding is key to the treatment of acute coronary syndromes

On Monday, September 4 and Tuesday, September 5 at the World Congress of Cardiology, Dr. Christopher Granger presented data stressing the importance of prevention of bleeding as a key objective in treatment of acute coronary syndromes.

5 Sep 2006

Saccharide complexes improve binding of Pentosanpolysulfate and Heparin to bladder epithelium

Anionic glycosaminoglycans including pentosanpolysulphate (PPS) and heparin show weak or no staining of the bladder epithelium and thus do not bind to human or rabbit bladder epithelium in any appreciable amounts.

17 Apr 2006

Sildenafil improves blood flow after heart attack in an animal model

Dogs treated with sildenafil, a drug most commonly used to treat erectile dysfunction, had better blood flow in coronary arteries than control animals, following an induced artery obstruction and treatment that modeled a heart attack and standard medical care given to people

13 Apr 2006

Fondaparinux significantly reduces risk of death for heart attack patients

Heart attack patients who have a certain pattern on an electrocardiogram significantly reduced their risk of death and having another heart attack at 30 days with the medication fondaparinux, without an increased risk of bleeding and strokes

15 Mar 2006

The safety and effectiveness of fondaparinux for heart attacks

The results of a large international cardiovascular trial will shed light on whether the addition of a new drug that prevents blood clotting, or thrombosis, can improve the treatment of the most serious form of heart attacks.

15 Mar 2006

Cutting angioplasty risks

Significant gains made through multi-hospital cooperative effort led by U-M Cardiovascular Center and funded by Blue Cross Blue Shield of Michigan.

16 Feb 2006

Alternative method to produce heparin

Researchers at Rensselaer Polytechnic Institute and University of North Carolina at Chapel Hill have discovered an alternative way to produce heparin, a drug commonly used to stop or prevent blood from clotting.

7 Feb 2006

Too high blood-thinner doses harmful to patients

According to a new analysis by cardiologists at the Duke Clinical Research Institute, in the prescribing of common but powerful anti-clotting drugs, 42 percent of patients rushed to emergency rooms with symptoms of a heart attack received doses intended to stop clotting in coronary arteries above the recommended range.

29 Dec 2005

Misdosing anti-clotting drugs leads to heart attack symptoms

Because of inaccuracies in prescribing, 42 percent of patients rushed to emergency rooms with symptoms of a heart attack received doses of powerful drugs intended stop clotting in coronary arteries outside of the recommended range, a new analysis by Duke Clinical Research Institute (DCRI) cardiologists has found.

28 Dec 2005

Physicians slow to prescribe newer heart drugs

An analysis of the treatment received by more than 100,000 heart patients has shown that physicians' prescription practices for drugs proven effective for treating heart disease has shown steady improvement over the past three years, cardiologists at the Duke Clinical Research Institute (DCRI) have concluded.

7 Dec 2005

Study of two drugs for angina treatment shows equal outcomes to patients

Researchers have found that the blood-thinning drug Lovenox works as well as a standard artery-clearing drug in patients with severe heart-related chest pain, but neither reduced the risk of death after a year of treatment.

24 Nov 2005

Myriad Genetics nears completion of antithrombin drug trial

Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.

11 Oct 2005

World's largest study on acute coronary syndromes

A Canadian-led study involving researchers from 41 countries has demonstrated in the world's largest study of acute coronary syndromes (ACS) that a new anti-thrombotic therapy is safer and as effective as the traditional therapy used in preventing heart attacks, death and ischemia in people with serious heart conditions.

5 Sep 2005

Reasons for complications with kidney failure patients

Mayo Clinic researchers searching for explanations of high mortality rates among kidney failure patients undergoing hemodialysis are focusing their attention on the use of heparin, a drug used to reduce clotting of the blood.

18 Aug 2005

Beta-blockers top choice for prevention and rate control for postoperative atrial fibrillation

The American College of Chest Physicians (ACCP) has released the first evidence-based clinical practice guidelines for the prevention and management of postoperative atrial fibrillation (AF) after cardiac surgery.

9 Aug 2005

Heparinase I is not a suitable replacement for protamine

The results of an international clinical trial led by Duke University Medical Center researchers has shown that a new drug is not a suitable replacement for protamine, a drug that has been used for more than 40 years after coronary artery bypass surgery to return thinned blood to its normal state.

1 Aug 2005